30060 Federal Register / Vol. 86, No. 106 / Friday, June 4, 2021 / Notices 

regarding information needed by 

Campaign audiences as well as their 

attitudes and behaviors related to 

COVID–19 and the COVID–19 vaccines. 

These will be used to inform the 

development of Campaign messages and 

strategy. 

Copy Testing Surveys 

Prior to placing Campaign 

advertisements in market, ASPA will 

conduct copy testing surveys to ensure 

the final Campaign messages have the 

intended effect on target attitudes and 

behaviors. Copy testing surveys will be 

conducted with sample members who 

comprise the target audiences; these 

surveys will assess perceived 

effectiveness of the advertisements as 

well as the effect of exposure to an ad 

on key attitudes and behavioral 

intentions. The results from these 

surveys will be used internally by ASPA 

to inform decisions on Campaign 

messages and materials; for example, to 

identify revisions to the materials or 

determine which advertisement to move 

to market. 

Need and Proposed Use: In light of 

the current COVID–19 crisis, this 

information is needed given the impact 

of the pandemic on the nation. The 

Secretary of the Department of Health 

and Human Services (HHS) has declared 

a public health emergency effective 

January 27, 2020, under section 319 of 

the Public Health Service Act (42 U.S.C. 

247d [1]) and renewed it continually 

since its issuance (see links to the 

determination here and here). 

Additionally, in accordance with 5 CFR 

1320.13, HHS previously requested 

emergency submissions (sections 1320 

(a)(2)(ii) and (2)(iii) of the federal 

regulations. 

ESTIMATED ANNUALIZED BURDEN HOUR TABLE

CET Foundational 

focus groups 

Copy testing 

survey 

Hours to screen ........................................................................................................................... N/A .09 0.03 

Screening completes (per wave) ................................................................................................. N/A 2,500 6,700 

Screening participants (total/screened out) ................................................................................. N/A 20,000/19,136 53,600/45,600 

Hours to complete survey/group ................................................................................................. 0.12 1.5 0.33 

Participants (per wave/round) ...................................................................................................... 1,000 108 1,000 

Number of waves/rounds ............................................................................................................. 92 8 8 

Burden per wave/round ............................................................................................................... 120 387 330 

Total participants .................................................................................................................. 92,000 864 8,000 

Total respondents * ............................................................................................................... 92,000 20,000 53,600 

Total burden hours ............................................................................................................... 11,040 3,096 4,248 

* Total respondents = total participants for each effort + total people screened out. 

Sum of All Studies 

Total Respondents: 165,600. 

Total Burden Hours: 18,384. 

Sherrette A. Funn, 

Paperwork Reduction Act Reports Clearance 

Officer, Office of the Secretary. 

[FR Doc. 2021–11723 Filed 6–3–21; 8:45 am] 

BILLING CODE 4150–25–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Integrated Preclinical/ 

Clinical AIDS Vaccine Development Program 

(IPCAVD) (U19 Clinical Trial Not Allowed). 

Date: June 30, 2021. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G36, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Poonam Pegu, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, DEA/NIAID/NIH/DHHS, 5601 

Fishers Lane, MSC–9823, Rockville, MD 

20892, 240–292–0719, poonam.pegu@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: May 28, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–11711 Filed 6–3–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Alcohol Abuse and Alcoholism Special 

Emphasis Panel; SARS-CoV–2, COVID–19 

and Consequences of Alcohol Use (RFA AA 

21–002, AA 21–003 and AA21–004). 

Date: July 15–16, 2021. 

Time: 9:00 a.m. to 6:00 p.m.